MGH Pet Core: Radiopharmaceuticals Available for Human and Animal Use
The Core has synthesized over 20 compounds for clinical evaluation and routine use for neurology, cardiology and oncology. In addition, it has pioneered the use of 18F Tau imaging agents for neurodegenerative diseases such as Alzheimer’s disease and traumatic brain injuries.
**FDA approved, available through local commercial nuclear pharmacies
†Active IND held by MGH PET Core
‡Available under Radioactive Drug Research Committee (RDRC) oversight
The MGH PET Core can validate a radiopharmaceutical for clinical research use.
- F-18 FDG* (tumour metabolism/hypometabolism)
- Florbetaben** (amyloid imaging) Flutemetamol** (amyloid imaging)
- Florbetapir** (amyloid imaging) Fluciclovine** (tumor metabolism/prostate cancer imaging)
- Sodium Fluoride** (bone imaging)
- FES (estrogen receptor)†
- Flortaucipir [T807] (tau protein)†
- FPEB (mGlur5)‡
- BFPET (myocardial perfusion) †
- FLT (cellular proliferation)†
- FMISO (hypoxia)†
- MK-6240 (tau protein) †
- C-11 PiB (amlyoid)†
- Altropane (Dopamine transport)‡
- Raclopride (D2/D3 receptor imaging) †
- Methionine (amino acid uptake)†
- Acetate (fatty acid synthase) †
- PBR-28 (TSPO/PBR)† (S,S)-[11C]Methylreboxetine (MeNR/MRB)‡ – targets norepinephrine transporter
- N-13
- Ammonia*
- N2 in Saline (lung perfusion imaging) ‡
- Ga-68
- DOTATATE** (neuroendocrine tumor imaging)
- Ga-68-PSMA-11
- FDOPA
**FDA approved, available through local commercial nuclear pharmacies
†Active IND held by MGH PET Core
‡Available under Radioactive Drug Research Committee (RDRC) oversight
The MGH PET Core can validate a radiopharmaceutical for clinical research use.